It has been reported that transforming growth factor-b induced CSCs of CD80 expression, an immune cell surface ligand, to block cytotoxic T-cell activity and mediate tumor resistance to adoptive cytotoxic T-cell transfer-based immunotherapy (41). The gene discussed is CD80; the disease is neoplasm.